

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The board (the “**Board**”) of the directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) hereby announces that Dr. Kam Biu Tsoi, Alvin (“**Dr. Tsoi**”) is appointed as an executive Director of the Company with effect from 30 June 2025.

The biographical details of Dr. Tsoi are set out as follows:

Dr. Tsoi Kam Biu, Alvin (蔡鑑彪), aged 69, is an Executive Director. Dr. Tsoi has over 40 years of experience in sales management and Chinese medicine and healthcare products. Dr. Tsoi is a consultant in The Hong Kong T. C. M. Orthopaedic and Traumatic Association Ltd. He is also an Honorary President and a consultant of The Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited. Dr. Tsoi is a listed Chinese Medicine Practitioner under the Chinese Medicine Practitioners Board of the Chinese Medicine Council of Hong Kong. Dr. Tsoi received his Doctorate Degree in Dental Medicine from De Ocampo Memorial College in the Philippines and obtained a Bachelor’s Degree in Chinese Medicine from the Chinese Medical Research Institute of the Association of Hong Kong and Kowloon Practitioners of Chinese Medicine Limited.

Dr. Tsoi has entered into a service contract with the Company for a term of three years commencing from 30 June 2025 and shall be renewed and extended automatically by one year on the expiry of such initial term and on the expiry of every successive period of one year thereafter, unless terminated by either the Company or Dr. Tsoi giving at least three months' written notice of termination before the expiry of the then existing term. Dr. Tsoi's appointment will be subject to retirement and re-election in accordance with the articles of association of the Company.

Pursuant to the service contract, Dr. Tsoi is entitled to an annual remuneration of HK\$1,440,000 payable by 12 monthly instalments, which is recommended by the remuneration committee of the Company and determined by the Board with reference to his duties and responsibilities undertaken and the prevailing market conditions with reference to the Company's policy on the Directors' and senior management's remuneration.

Dr. Tsoi was appointed as Director of the Company on 2 December 2011 and was re-designated as an executive Director on 22 April 2014. He resigned on 28 May 2021 due to personal reason. As at the date of this announcement, Dr. Tsoi beneficially owns 2,572,000 shares in the Company. Save as disclosed above, Dr. Tsoi does not have any interest in the shares in the Company or any of its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

As at the date of this announcement and save as disclosed above:

- (i) Dr. Tsoi has not held any other major appointment and qualification or directorship in other listed companies in Hong Kong or overseas in the three years preceding the date of this announcement;
- (ii) Dr. Tsoi does not hold any other position in the Company or members of the Group;
- (iii) Dr. Tsoi does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders (having the meaning ascribed to it under the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**")) of the Company; and

- (iv) there is no other information which is required to be disclosed pursuant to the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules or there are no any other matters that ought to be brought to the attention of the shareholders of the Company in relation to the appointment of Dr. Tsoi as an executive Director.

The Board would like to express its warmest welcome to Dr. Tsoi for joining the Board.

CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE

The Board hereby announces the following changes in the composition of the nomination committee of the Board (the “**Nomination Committee**”) with effect from 30 June 2025:

1. Ms. Man Yee Wai Viola (“**Ms. Man**”), an executive Director, has been appointed as a member of the Nomination Committee; and
2. Dr. Leung Lim Kin Simon (“**Dr. Leung**”), an independent non-executive Director, has been appointed as a member of the Nomination Committee.

Other positions held by Ms. Man and Dr. Leung at the Board and other Board committees remain unchanged.

Following the above changes, the Nomination Committee will comprise two executive Directors (namely, Chan Yu Ling Abraham, chairman of the Nomination Committee, and Ms. Man) and three independent non-executive Directors (namely, Mr. Ho Kwok Wah George, Dr. Leung and Prof. Tsui Lap Chee).

The above changes were made in response to the amendments to the Listing Rules and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, which require the appointment of at least one director of a different gender to the nomination committee and will come into effect on 1 July 2025. As such, Ms. Man a female Director, has been appointed as a member of the Nomination Committee. And the Nomination Committee should comprise of a majority of independent non-executive directors who meet the independence requirements as stipulated in the Listing Rules. As such, Dr. Leung, an independent non-executive Director, has been appointed as a member of the Nomination Committee. The Board believes that implementing these changes could strengthen the effectiveness and diversity of the Board, and further enhances good corporate governance practices of the Company as a whole.

The Board would like to extend a warm welcome to Ms. Man and Dr. Leung on their new role in the Nomination Committee.

By order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 30 June 2025

As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola, and Dr. Tsoi Kam Biu, Alvin; the non-executive Director is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.